ThromboGenics (THR)

Business description

ThromboGenics is a Belgian biopharmaceutical company focused on developing and commercialising the eye drug ocriplasmin; EU (via Alcon) and US launches are due in Q113. Antibody candidates targeting cardiovascular disorders and cancer are in mid-stage clinical trials.

Vision to deliver

QuickView | Pharmaceutical & healthcare | 21/03/2012

Securing Alcon (Novartis) as an ex US partner for eye drug ocriplasmin is a significant milestone in ThromboGenics’ path to becoming a fully-integrated pharmaceutical company. Shares in the Belgian company have gained 9% since the deal and now trade at record highs. With burgeoning expectations comes increasing pressure to deliver. The Alcon deal, with €165m in near-term payments, provides ocriplasmin with the best possible start in Europe and lends significant financial support to ThromboGenics’ own launch plans in the US.

Edison's research is freely available. We will never ask for your credit card details and you do not need to register. By downloading this research you are agreeing to our terms and conditions, which you can read in full here.